DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167.

德国达姆施塔特-（商业线）-领先的科技公司默克今天宣布与江苏恒瑞制药有限公司（恒瑞）进行战略合作。该合作伙伴关系包括全球独家许可（ex China），用于开发，制造和商业化恒瑞的下一代强效选择性PARP1（聚（ADP-核糖）聚合酶1）捕获抑制剂HRS-1167。

The agreement also includes an option to an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s Claudin-18.2 antibody-drug conjugate (ADC) SHR-A1904. In addition, Merck has the option to co-promote both assets in China..

该协议还包括在全球范围内（ex China）开发，制造和商业化恒瑞Claudin-18.2抗体-药物偶联物（ADC）SHR-A1904的独家许可选择。此外，默克可以选择在中国共同促进这两项资产。。

“This partnership with Hengrui fully aligns with both our external innovation ambition and our oncology research and development strategy by diversifying our robust internal pipeline in our focus areas of DNA damage response inhibition and antibody-drug conjugates,” said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business of Merck.

全球负责人Danny Bar Zohar说：“与Hengrui的这种合作关系完全符合我们的外部创新雄心壮志和我们的肿瘤学研发战略，使我们在DNA损伤反应抑制和抗体-药物偶联等重点领域的强大内部渠道多样化。默克医疗保健业务研发和首席医疗官。

“The synergies of these assets with our portfolio offer broad potential for development and the opportunity to advance more therapeutic options for patients with difficult-to-treat cancers. We look forward to leveraging the significant expertise of Hengrui and our strong collaboration ahead.”.

“这些资产与我们的投资组合的协同作用为开发提供了广泛的潜力，并有机会为难以治疗的癌症患者提供更多的治疗选择。我们期待利用恒瑞的重要专业知识和我们的强大合作。”。

Compared with first-generation PARP inhibitors, the selectivity and differentiated safety profile of PARP1-specific inhibitors could offer the opportunity to expand their therapeutic impact in established and new indications. HRS-1167 has shown encouraging signs of clinical activity and patient benefit in Phase I trials as a monotherapy and has higher potential to combine with chemotherapy as well as novel agents, compared with previous attempts with first-generation PARP inhibitors.

与第一代PARP抑制剂相比，PARP1特异性抑制剂的选择性和差异化安全性可为扩大其在既定和新适应症中的治疗效果提供机会。与先前使用第一代PARP抑制剂的尝试相比，HRS-1167在I期试验中作为单一疗法显示出令人鼓舞的临床活性和患者益处的迹象，并且具有与化学疗法以及新药组合的更高潜力。

This aligns with the company’s overarching development approach of DNA damage response (DDR) inhibitors, exploring their synergistic activity and maximizing their potential impact in combination with other anticancer therapies and approaches. Merck is researching the potential to treat cancer through inhibition of multiple targets in the DDR cascade, including ATR, ATM, DNA-PK, and PARP..

这与公司DNA损伤反应（DDR）抑制剂的总体开发方法相一致，探索其协同活性，并结合其他抗癌疗法和方法最大限度地发挥其潜在影响。默克正在研究通过抑制DDR级联中的多个靶点来治疗癌症的潜力，包括ATR，ATM，DNA-PK和PARP。。

Additionally, should the company exercise its option, SHR-A1904 would complement Merck’s internal preclinical and clinical ADC portfolio applying different linker payload technologies. The first ADC developed using Merck’s own technology, M9140, a CEACAM5-targeting ADC, is being evaluated in an ongoing Phase Ia/b study in patients with metastatic colorectal cancer..

此外，如果公司行使其选择权，SHR-A1904将补充默克内部的临床前和临床ADC组合，应用不同的连接器有效负载技术。使用默克自己的技术开发的第一个ADC，M9140，一种靶向CEACAM5的ADC，正在进行的转移性结直肠癌患者的Ia/b期研究中进行评估。。

'Given the high unmet need in oncology, we are excited to work closely with Merck to bring Hengrui's innovations to cancer patients worldwide,” said Frank Jiang, board member and Chief Strategy Officer of Hengrui Pharma. “Partnering with Merck on our PARP franchise is an important milestone on Hengrui's globalization journey.

恒瑞制药公司董事会成员兼首席战略官弗兰克·江（Frank Jiang）说：“鉴于肿瘤学需求尚未得到满足，我们很高兴与默克公司密切合作，为全球癌症患者带来恒瑞的创新。”。“与默克合作我们的PARP特许经营是恒瑞全球化历程的重要里程碑。

We look forward to advancing our molecules rapidly through development and reaching patients in need.”.

我们期待通过开发和接触需要帮助的患者来快速推进我们的分子。”。

Under the terms of the agreement, Merck will provide Hengrui with an upfront payment of €160 million. Hengrui will receive payments for the achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Merck. Potential payments may total up to €1.4 billion..

根据协议条款，默克将为恒瑞提供1.6亿欧元的预付款。恒瑞将为实现默克净销售的某些发展，监管和商业里程碑以及分层版税支付。潜在付款总额可能高达14亿欧元。。

Advancing the Future of Cancer Care

推进癌症治疗的未来

At Merck, we strive every day to improve the futures of people living with cancer. Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at its core. We are determined to maximize the impact of our standard-of-care treatments and to continue pioneering novel medicines.

在默克，我们每天都在努力改善癌症患者的未来。我们的研究探索了癌症研究中有希望的机制的全部潜力，重点是旨在以癌症为核心的协同方法。我们决心最大限度地发挥我们的护理标准治疗的影响，并继续开拓新药。

Our vision is to create a world where more cancer patients will become cancer survivors. Learn more at www.merckgrouponcology.com..

我们的愿景是创造一个更多癌症患者将成为癌症幸存者的世界。在www.merckgroup oncology.com了解更多信息。。

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

所有默克新闻稿都是在默克网站上发布的同时通过电子邮件分发的。请访问www.merckgroup.com/subscribe在线注册，更改您的选择或停止此服务。

About Merck

默克

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere.

默克是一家领先的科技公司，在生命科学，医疗保健和电子领域开展业务。超过64000名员工通过创造更多快乐和可持续的生活方式，每天为数百万人的生活做出积极的改变。从提供加速药物开发和制造的产品和服务，以及发现治疗最具挑战性疾病的独特方法到实现设备智能，公司无处不在。

In 2022, Merck generated sales of € 22.2 billion in 66 countries..

2022年，默克在66个国家实现了222亿欧元的销售额。。

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand.

科学探索和负责任的创业是默克技术和科学进步的关键。这就是默克自1668年成立以来如何蓬勃发展。创始家族仍然是上市公司的多数所有者。默克拥有默克名称和品牌的全球权利。

The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics..

唯一的例外是美国和加拿大，默克的商业部门在生命科学领域以MilliporeSigma，医疗保健领域的EMD Serono和电子领域的EMD Electronics运作。。